Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial

PHASE2TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

May 7, 2020

Study Completion Date

July 1, 2020

Conditions
COPDEBV
Interventions
DRUG

Valaciclovir

Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.

DRUG

Placebo capsules (containing Avicel blend)

Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.

Trial Locations (1)

BT5 7GX

Belfast Health and Social Care Trust, Belfast

Sponsors
All Listed Sponsors
collaborator

Northern Ireland Clinical Trials Unit

OTHER

collaborator

Queen's University, Belfast

OTHER

lead

Belfast Health and Social Care Trust

OTHER

NCT03699904 - Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial | Biotech Hunter | Biotech Hunter